In a mouse model of breast cancer, treatment with Met‐CCL5 (a CCR5 antagonist) for 5 continuous weeks resulted in significant reductions in tumor volume and weight compared with those of control tumors, indicating the activity of Met‐CCL5 against established tumors [166]. Here, CCL5 is linked to breast carcinoma.